Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Discussing Guidance On Giving Drug Economic Data To Formulary Managers

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA official Tom Abrams recently acknowledged heightened stakeholder interest in guidance on appropriate communications of health care economic data under FDAMA Sec. 114.

You may also be interested in...



Rx Firms Still Bear Promotional Compliance Burden If Social Media Platform Changes, FDA Says

Agency’s advertising office Director Tom Abrams offers hints of FDA’s thinking ahead of the infamously delayed social media guidance.

Health Economic Promotions To Formulary Managers: Seldom Used Or Under The Radar?

A review of FDA enforcement actions against drug marketing practices over the past 10 years finds no mention of specific violations of Sec. 114 of the FDA Modernization Act, which allows drug companies to take the initiative to disseminate health economic information to formulary managers in certain circumstances.

Is Aducanumab In Alzheimer’s A Candidate For Medicare ‘Coverage With Evidence Development’?

Medicare may look to bolster evidence on Biogen’s potential Alzheimer’s treatment, if approved, with a national coverage decision requiring the collection of clinical data in the postmarket setting.

Topics

UsernamePublicRestriction

Register

PS075983

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel